Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Sponsor
Fudan University
Study ID
NCT03797625
Phase
PHASE2
Status
Completed

Conditions

  • Esophageal Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Irinotecan — DRUG
    60mg/m2，D1，8
  • DDP — DRUG
    60mg/m2，D1
  • Endostar — DRUG
    15mg/d，d1-d7 civ

Study Details

The aim of this study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens

Key Dates

Start date
May 4, 2017
Status verified
Jul 2025
Primary completion
Dec 31, 2020
Completion
Dec 31, 2021

Study Design

Enrollment
52 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Endostar Combined With IP
    Endostar15mg/m2 Irinotecan 60mg/m2，D1，8 DDP 60mg/m2，D1

Primary Outcome Measure

Progression Free Survival [ Time Frame: from the first cycle of treatment (day one) to two month after the last cycle ]

Related Studies